Cargando…

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1

Human programmed cell death protein 1 (PD-1) is a checkpoint protein involved in the regulation of immune response. Antibodies are widely used as inhibitors that block the immune checkpoint, preventing strong immune responses. Pembrolizumab is an FDA-approved IgG4 antibody with PD-1 inhibitory abili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Simiao, Khan, Faez Iqbal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341962/ https://www.ncbi.nlm.nih.gov/pubmed/37445859 http://dx.doi.org/10.3390/ijms241310684

Ejemplares similares

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
por: Na, Zhenkun, et al.
Publicado: (2017)

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
por: Horita, Shoichiro, et al.
Publicado: (2016)

Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry
por: Tavares, Ana Beatriz M. L. A., et al.
Publicado: (2018)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method
por: Lim, Hocheol, et al.
Publicado: (2019)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

The Molecular Basis of the Effect of Temperature on the Structure and Function of SARS-CoV-2 Spike Protein
por: Khan, Faez Iqbal, et al.
Publicado: (2022)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

SAT-242 Isolated Adrenocorticotropic Hormone Deficiency Secondary to the PD-1 Inhibitor Pembrolizumab
por: Mathew, Justin, et al.
Publicado: (2020)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

THU374 Fulminant Type 1 Diabetes Mellitus And DKA Secondary To Pembrolizumab
por: Iqbal, Iqra, et al.
Publicado: (2023)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report
por: Li, Sicheng, et al.
Publicado: (2018)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
por: Mehnert, Janice M., et al.
Publicado: (2019)

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
por: Isshiki, Takuma, et al.
Publicado: (2018)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations
por: Khan, Faez Iqbal, et al.
Publicado: (2021)

Molecular predictors of response to pembrolizumab in thymic carcinoma
por: He, Yongfeng, et al.
Publicado: (2021)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
por: Lyu, Mengmeng, et al.
Publicado: (2020)

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
por: Verhoeven, Yannick, et al.
Publicado: (2021)

Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer
por: Pagkopoulou, Eleni, et al.
Publicado: (2020)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Dosimetry Prediction for Clinical Translation of (64)Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression
por: Natarajan, Arutselvan, et al.
Publicado: (2018)

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b9gsijphsb7iebl3e294m4me19